Paradigm Shifts in Hemophilia Prophylaxis: Putting Evidence Into Practice

Stay informed with the newest clinical trial findings on hemophilia prophylaxis, covering extended half-life factor replacement treatments and emerging nonfactor therapies aimed at rebalancing hemostasis. Access downloadable slides, a CME-certified webcast, and expert commentary answering common questions about hemophilia prophylaxis.

Share

Program Content

Activities

Hemophilia: Advances in Factor Replacement Tx
Current Treatment Paradigm for Hemophilia and Advances in Factor Replacement Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 05, 2024

Expires: April 04, 2025

Novel Nonfactor Tx in Hemophilia
Clinical Implications on the Role of Novel Nonfactor Therapy to Improve Patient Outcomes
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 05, 2024

Expires: April 04, 2025

Activities

Paradigm shifts in hemophilia prophylaxis
Paradigm Shifts in Hemophilia Prophylaxis: Putting Evidence Into Practice
Video
Congratulations: You achieved a completion on 04/09/2022

Released: April 22, 2024

Expires: April 21, 2025

Faculty

cover img faculity

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

cover img faculity

Mark T. Reding, MD

Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

cover img faculity

Angela C. Weyand, MD

Clinical Associate Professor of Pediatrics
Division of Hematology/Oncology
University of Michigan Medical School
Ann Arbor, Michigan

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Sanofi.

Sanofi